Resistance to chemotherapeutic drugs and radiation represents a major obstacle in human cancer therapy. Since DNA is the most important target of many cytotoxic agents, the capacity for repair of specific, drug-induced DNA lesions may be an important determinant in the response of cancer cells to treatment, in addition to other mechanisms, such as drug transport and detoxification (reviewed, for example, by, Epstein, 1990; Burt et al., 1991; Ross & Brown, 1992) . However, comparatively little is known about the DNA repair capacity of malignant cells derived from patients. This is mainly because of the lack of sufficiently sensitive methods of quantifying specific DNA adducts and the rate of their elimination from DNA in small cell samples or in individual cells.
Mono-or bifunctional alkylating agents such as nitrosoureas, procarbazine, cyclophosphamide, mitomycin C, BCNU, busulphan and chlorambucil form cytotoxic and mutagenic DNA adducts via covalent bonds to nucleophilic sites, preferentially at the N7-and 06-atoms of guanine (Colvin & Chabner, 1990) . Guanine-06 alkylation products in DNA are very efficiently repaired by a specific DNA alkyltransferase (AT; EC 2.1.1.63; Pegg, 1990) and, more slowly, by alternative pathways such as base or nucleotide excision (Boyle et al., 1986a, b; Bronstein et al., 1992a, b; SibghatUllah & Day, 1992) .
In human cells, e.g. normal cells or cells derived from tumours, autopsy material, surgical biopsies or fetal tissues, significant differences in cellular AT protein levels among different tissues have been reported (Gerson et al., 1986; D'Incalci et al., 1988; Fornace et al., 1990; Vahakangas et al., 1991; Chen et al., 1992; Wani et al., 1993) . Moreover, considerable inter-individual variability has been observed for a given type of cells (Kyrtopoulos et al., 1990 ; Strauss, 1990; Citron et al., 1991; Redmond et al., 1991) . Thus, in peripheral human lymphocytes inter-patient variations in AT levels up to a factor of 9 have been reported (Sagher et al., 1988; Gerson, 1989; Lee et al., 1991; Panella et al., 1992) . Plausible relationships have been proposed between cell type and individual sensitivity to the cytotoxic effects of alkylating or chloroalkylating agents on the one hand and the levels of cellular AT activity on the other (Brent et al., 1985; Dolan et al., 1989; Pieper et al., 1991; Panella et al., 1992) . Other (Silber et al., 1992; Bobola et al., 1993; Chen et al., 1993) . Godfrey et al. (1992) have suggested that cellular resistance to the cytotoxic effect of 06-alkylguanines (06-AlkGua) persisting in DNA could also be caused by mechanisms other than DNA repair, such as 'postreplication recovery'.
An increasing body of evidence indicates that DNA damage and the repair of specific DNA lesions is heterogeneous among individual cells (e.g. in biopsy material, Scherer et al., 1989; Wani et al., 1993) and throughout genomic DNA (Bohr, 1991; Le Doux et al., 1991; . However, only very recently, sufficiently sensitive analytical methods have become available which permit us to quantify specific drug-induced DNA lesions in defined gene sequences (Hochleitner et al., 1991; Zhen et al., 1992) and in single cells (Frankfurt et al., 1990; Van Delft et al., 1991; Seiler et al., 1993) . In the present study, we have applied a newly developed, monoclonal antibody (MAb)-based immunocytological assay (ICA; Seiler et al., 1993) to measure the repair kinetics of 06-AlkGua in the nuclear DNA of individual human lymphocytes and leukaemic blasts after pulse exposure to N-alkyl-N-nitrosoureas. This class of compounds is particularly suitable as prototype substances because the reaction kinetics and all major reaction products with DNA are well characterised. Moreover, we have determined the influence of 06-benzylguanine (06-BeGua), an inhibitor of cellular AT activity (Dolan et al., 1990) , on the persistence of 06-alkylguanines in the DNA of these cells. Determination of AT activity in cell extracts AT activity in cell extracts was determined essentially as described by Pegg et al. (1982) . Briefly, cells were suspended in extraction buffer (50 mM Tris-HCl, pH 7.8, 100 mM sodium chloride, 1 mM DTT, 1 mM EDTA, 5% glycerol), sonicated (3 x 5 s; 0°C) and cell debris was removed by centrifugation (Omin; 12,000 g; O°C) as previously described (Nehls & Rajewsky, 1990 Figure 4 . Of -24,000 06-EtGua residues formed on average per diploid genome, these cells eliminated -12,000 adducts (50%) within 3 h after EtNU exposure, and -22,000 adducts (90%) within 17 h. As determined by flow cytometry in parallel, 95% of cells were in the G, phase of the cell cycle or in Go (data not shown). tendency to slightly increased variations (CV 30-50%) at lower DNA adduct levels. The contribution of the suicidal DNA repair protein AT to the elimination of 06-EtGua from DNA was determined by 1.5 h preincubation of cells with the AT inhibitor o6-benzylguanine (25 rLM) prior to EtNU exposure. The repair kinetics of lymphocytes from a normal donor (Figure 7a ) and from a CLL patient (Figure 7b and (Figure 7b ). Under AT blocking by o6-BeGua before, during and after ethylation, 06-EtGua was still eliminated from DNA, but less rapidly by a factor of 9 (t-18 h) as compared with untreated cells (t1 = 2 h; see Table I ).
Materials and methods

Isolation
Elimination of 06-BuGua from the DNA of lymphocytes or leukaemic blasts after pulse exposure to BuNU For selected cell samples the persistence of 06-BuGua in nuclear DNA was determined in parallel. To induce an equimolar amount of O6-guanine alkylation in DNA by BuNU (Saffhill, 1984) , cells were exposed to 300 tg ml-1 BuNU for 20 min (standard conditions), resulting in -25,000 06-BuGua residues per diploid genome (as determined in DNA isolated from cell aliquots by immunoslotblot analysis; data not shown). The elimination of 06-BuGua and 06-EtGua from the DNA of AML blast cells exposed to BuNU and EtNU, respectively, followed different kinetics. While 06-EtGua was repaired with typical biphasic kinetics (t1 = 3.4 h), 06-BuGua elimination was much slower (t1 = 13.5 h), exhibiting linear repair characteristics ( Figure   8 ). ti values for 06-BuGua were generally higher by a factor of 3-5 in comparison with the elimination of equimolar amounts of 06-EtGua (as shown for various cell samples in Figure 9 ). In one case of CLL, however, elimination of both alkylation products was much more rapid (tj<l h), exhibiting no difference between the repair of 06-EtGua and 06-BuGua within the time intervals analysed.
Discussion
Although the potential of DNA repair in mediating the resistance of cancer cells to DNA-reactive drugs has been 1 1 recognised for a long time, little is known so far about its clinical significance. This is mainly because of the lack of sensitive and reliable assays to quantify specific DNA lesions in small samples of cells from cancer patients. In the present study, we have applied a recently established MAb-based immunoanalytical assay for the quantification of specific lesions in the nuclear DNA of individual cells (Seiler et al., 1993) to measure directly the kinetics of elimination (repair) of 06-AlkGua residues from DNA in human peripheral lymphocytes and leukaemic blasts. Among the lymphocytes or blast cells isolated from individual donors, comparatively uniform intercellular formation and repair of 06-EtGua in DNA were observed after pulse exposure to EtNU in vitro. Within groups of 100 cells analysed per time point, major (> 10%) cell subpopulations differing significantly from the remaining cells with respect to O6-EtGua elimination from nuclear DNA were not detected. Repair variants present at lower frequencies may be identified by adapting the immunoanalytical procedure used here to flow cytometric techniques.
The 06-EtGua 'repair phenotype' of the normal lymphocytes of a given individual was rather stable, i.e. no major variations were observed regarding the persistence of o6-EtGua in cells isolated from the same donor at different times over a period of 1 week, although the distributions of t1 values became somewhat broader (± 25% of the mean) during long-term observations for up to several months. In contrast, the persistence of 06-EtGua in nuclear DNA of lymphocytes and leukaemic blasts exhibited wide inter- Leung, 1986; Sagher et al., 1988; Strauss, 1990; Lee et al., 1991; Souliotis et al., 1991) After blocking cellular AT activity by preincubating cells with 06-BeGua, elimination of 06-EtGua from DNA of normal and leukaemic lymphocytes was decelerated considerably, but not entirely abolished. Thus, after reducing the level of active AT by 06-BeGua to 1% of untreated controls (Table I) , 06-EtGua was still repaired with t, = 4 h in a sample of normal lymphocytes (Figure 7) . This observation suggests that, in distinct cell samples, the kinetics of O6-EtGua elimination from DNA may result from more than one repair mechanism: a very fast-reacting, 06-BeGuasensitive component (AT) and a second, more slowly acting system unaffected by 06-BeGua. It remains to be determined whether this second component represents a 'back-up' excision repair pathway or another repair mechanism.
It has been shown that the bacterial UVR excision repair complex efficiently eliminates 06-methyl-and -ethylguanine from DNA in vivo (Samson et al., 1988) . Experiments designed to detect a similar activity in extracts of rodent and human cells using double-stranded oligonucleotides contain- for 06-EtGua in nuclear DNA of lymphocytes. Cells from three healthy donors (P1, P2, P3) were isolated on consecutive days, exposed to EtNU in vitro, and the kinetics of 06-EtGua elimination from DNA was determined as described in Time after EtNU pulse (h) Figure 6 Inter- Figures 2 and 3) ; time intervals (tj) for removal of 50% of 06-EtGua residues from nuclear DNA were determined from the repair kinetics.
Time after EtNU pulse (h) Figure 7 Influence of the AT inhibitor 06-benzylguanine on the elimination from DNA of 06-EtGua in lymphocytres in vitro. Lymphocytes isolated from a healthy donor (a) and from a CLL patient (b) were exposed to EtNU (100 pg ml-') in vitro and analysed for their 06-EtGua content in DNA at different times as described (Figures 2 and 3) . Throughout the experiment cells were either kept in normal RPMI medium (0) or in medium supplemented with 06-benzylguanine (25 jiM) 1.5 h prior to EtNU exposure and throughout the entire experimental period (A), or pretreated with 06-benzylguanine for 1.5 h only, followed by a change to normal medium after exposure to EtNU (A). Figure 7 ). ing 06-MeGua opposite cytosine have thus far failed (Karran & Bignami, 1992; Sibghat-Ullah & Day, 1992; Branch et al., 1993) . It is still unclear whether an excision repair mechanism defective in xeroderma pigmentosum may complement ATmediated repair of 06-EtGua, as postulated by Bronstein et al. (1992a, b) . The characterisation of multiple, overlapping DNA repair systems for the elimination of alkylation damage from the DNA of mammalian cells may help us to understand inconsistent results on the relevance of AT activity levels for the resistance of cancer cells to the cytotoxicity of mono-and bifunctional alkylating agents. In a variety of human primary tumour cells, tumour cell lines and human xenografts in rodents, an inverse correlation has been observed between cellular AT activity and cell killing by this class of anticancer drugs (Brent et al., 1985; Cohen & Leung, 1986; Gerson et al., 1988a, b; Dolan et al., 1989 Dolan et al., , 1990 Dolan et al., , 1991 Gonzaga et al., 1992; Mitchell et al., 1992; Panella et al., 1992; Baer et al., 1993) . On the other hand, different levels of AT activity did not significantly influence cellular sensitivity to BCNU or EtNU in a number of human cell types, e.g. glioblastoma cell lines, brain tumours or lymphocytes (Silber et al., 1992; Walker et al., 1992; Bobola et al., 1993; Muller et al., 1993) .
Although 06-BuGua may be eliminated from DNA by purified mammalian AT protein in vitro (Morimoto et al., 1985) , the predominant involvement of an excision repair mechanism in the elimination of this lesion from DNA in vivo is suggested by experimental data obtained by Boyle et al. (1986a, b) . Moreover, these authors have shown that excision repair activity in human tumour cell lines is correlated with the cells' ability to excise bulky DNA lesions. (Eli) and 06-BuGua ( ) in the DNA of lymphocytes and leukaemic blasts. Cells were isolated from patients with CLL or AML or from healthy individuals, and aliquotes were exposed to EtNU (I00 lg ml -) or BuNU (300 jig ml-'), in vitro. The content of 0-alkylguanines in nuclear DNA at different times after alkylation was determined by immunofluorescence analysis in 100 cells per sample. The t4 values for the content of 06-alkylguanines in nuclear DNA were deduced from the elimination curves. (In the case of the CLL specimen, both adducts were below the detection limit at tl.5 h; the t1 values were estimated to be <1 h.)
provide information on the possible dependence of cellular drug resistance on DNA excision repair capacity. In four out of five cell samples analysed for repair of 06-EtGua and 06-BuGua in parallel, we found similar long persistence of the butyl residue (t1 values between 6 and 16 h). However, one sample of CLL lymphocytes exhibited extremely rapid elimination of both DNA alkylation products (t1 <1 h). Interestingly, these cells were isolated from a patient who later proved to be highly resistant to chemotherapy with alkylating agents. These findings, together with the observation that cellular AT pools and 'residual' repair capacities after AT blocking are correlated (Table I) , may indicate an (incidential) coregulation of different DNA repair systems. The aim of the present study was to develop a sensitive and reliable technique for determining, at the single-cell level, the capacity of cancer cells derived from patients to repair specific drug-induced DNA lesions. Because of the small number of samples analysed, we are not yet able to relate the DNA repair capacity of malignant cells to clinical status. Further studies should, therefore, apply this immunocytological assay for the differential repair of critical DNA lesions to a larger number of human cell samples in order to correlate the results to in vitro drug sensitivity profiles to the effects of different drug resistance (DNA repair) modifiers and to clinical data. These analyses will contribute to a better appreciation of the relevance of DNA repair mechanisms to therapy resistance and to the design of individualised regimens for cancer chemotherapy.
